Mitchell McLeod Pugh & Williams’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $913K | Hold |
15,053
| – | – | 0.13% | 136 |
|
|
2025
Q4 | $933K | Sell |
15,053
-406
| -3% | -$19.5K | 0.13% | 136 |
|
|
2025
Q3 | $662K | Buy |
15,459
+445
| +3% | +$20.8K | 0.11% | 155 |
|
|
2025
Q2 | $695K | Buy |
15,014
+613
| +4% | +$30.1K | 0.13% | 147 |
|
|
2025
Q1 | $878K | Buy |
14,401
+3,048
| +27% | +$178K | 0.18% | 118 |
|
|
2024
Q4 | $642K | Sell |
11,353
-17
| -0.1% | -$950 | 0.13% | 145 |
|
|
2024
Q3 | $588K | Buy |
11,370
+3
| +0% | +$141 | 0.12% | 157 |
|
|
2024
Q2 | $472K | Sell |
11,367
-7,675
| -40% | -$343K | 0.11% | 169 |
|
|
2024
Q1 | $1.03M | Buy |
19,042
+60
| +0.3% | +$3.06K | 0.25% | 92 |
|
|
2023
Q4 | $974K | Sell |
18,982
-203
| -1% | -$10.7K | 0.26% | 90 |
|
|
2023
Q3 | $1.11M | Buy |
19,185
+358
| +2% | +$21.9K | 0.33% | 76 |
|
|
2023
Q2 | $1.2M | Sell |
18,827
-133
| -0.7% | -$8.92K | 0.35% | 73 |
|
|
2023
Q1 | $1.31M | Sell |
18,960
-125
| -0.7% | -$8.82K | 0.41% | 65 |
|
|
2022
Q4 | $1.37M | Sell |
19,085
-1,013
| -5% | -$76.4K | 0.46% | 59 |
|
|
2022
Q3 | $1.43M | Sell |
20,098
-98
| -0.5% | -$7.11K | 0.55% | 49 |
|
|
2022
Q2 | $1.55M | Sell |
20,196
-572
| -3% | -$43.6K | 0.6% | 43 |
|
|
2022
Q1 | $1.52M | Buy |
20,768
+865
| +4% | +$58.1K | 0.51% | 57 |
|
|
2021
Q4 | $1.24M | Buy |
19,903
+1
| +0% | +$59 | 0.41% | 69 |
|
|
2021
Q3 | $1.18M | Buy |
19,902
+1,252
| +7% | +$82.5K | 0.44% | 68 |
|
|
2021
Q2 | $1.25M | Sell |
18,650
-1,473
| -7% | -$96K | 0.48% | 60 |
|
|
2021
Q1 | $1.27M | Buy |
20,123
+149
| +0.7% | +$9.27K | 0.53% | 54 |
|
|
2020
Q4 | $1.24M | Sell |
19,974
-26
| -0.1% | -$1.6K | 0.57% | 53 |
|
|
2020
Q3 | $1.21M | Buy |
20,000
+76
| +0.4% | +$4.57K | 0.62% | 46 |
|
|
2020
Q2 | $1.17M | Buy |
19,924
+8,000
| +67% | +$479K | 0.67% | 46 |
|
|
2020
Q1 | $665K | Buy |
11,924
+257
| +2% | +$15.7K | 0.51% | 68 |
|
|
2019
Q4 | $749K | Buy |
11,667
+5,702
| +96% | +$327K | 0.47% | 74 |
|
|
2019
Q3 | $302K | Buy |
5,965
+460
| +8% | +$21.6K | 0.2% | 148 |
|
|
2019
Q2 | $250K | Buy |
5,505
+150
| +3% | +$6.99K | 0.17% | 159 |
|
|
2019
Q1 | $255K | Hold |
5,355
| – | – | 0.18% | 153 |
|
|
2018
Q4 | $278K | Sell |
5,355
-500
| -9% | -$26.9K | 0.22% | 141 |
|
|
2018
Q3 | $363K | Sell |
5,855
-27
| -0.5% | -$1.6K | 0.24% | 141 |
|
|
2018
Q2 | $325K | Buy |
5,882
+27
| +0.5% | +$1.46K | 0.23% | 144 |
|
|
2018
Q1 | $370K | Hold |
5,855
| – | – | 0.26% | 136 |
|
|
2017
Q4 | $359K | Hold |
5,855
| – | – | 0.25% | 134 |
|
|
2017
Q3 | $373K | Hold |
5,855
| – | – | 0.27% | 128 |
|
|
2017
Q2 | $326K | Buy |
5,855
+2
| +0% | +$109 | 0.25% | 133 |
|
|
2017
Q1 | $318K | Buy |
5,853
+1
| +0% | +$55 | 0.25% | 136 |
|
|
2016
Q4 | $342K | Buy |
5,852
+2
| +0% | +$109 | 0.28% | 128 |
|
|
2016
Q3 | $316K | Buy |
5,850
+1
| +0% | +$64 | 0.28% | 122 |
|
|
2016
Q2 | $430K | Buy |
5,849
+200
| +4% | +$14.1K | 0.39% | 93 |
|
|
2016
Q1 | $361K | Sell |
5,649
-338
| -6% | -$21.3K | 0.35% | 101 |
|
|
2015
Q4 | $412K | Hold |
5,987
| – | – | 0.41% | 92 |
|
|
2015
Q3 | $354K | Hold |
5,987
| – | – | 0.37% | 98 |
|
|
2015
Q2 | $398K | Hold |
5,987
| – | – | 0.37% | 100 |
|
|
2015
Q1 | $386K | Buy |
5,987
+400
| +7% | +$25K | 0.35% | 104 |
|
|
2014
Q4 | $330K | Buy |
+5,587
| New | +$315K | 0.31% | 116 |
|
Other funds holding BMY
VCM
VPM
Mitchell McLeod Pugh & Williams's BMY Position: Q1 2026 in Review
Mitchell McLeod Pugh & Williams held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 15,053 shares worth $913K. The position accounts for 0.13% of the portfolio, ranked #136.
Mitchell McLeod Pugh & Williams first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.55M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Mitchell McLeod Pugh & Williams held 15,053 shares of Bristol-Myers Squibb worth $913K as of Q1 2026.
- Mitchell McLeod Pugh & Williams left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.13% of Mitchell McLeod Pugh & Williams's portfolio in Q1 2026, its #136 holding.
- Mitchell McLeod Pugh & Williams first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
- Mitchell McLeod Pugh & Williams's Bristol-Myers Squibb position peaked at $1.55M in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Mitchell McLeod Pugh & Williams's 13F filing for Q1 2026, filed 24 Apr 2026.